Avacta Group plc (AVCT) Ordinary Shares 10p
![](https://online.hl.co.uk/img/hl/layout/security-up-arrow.gif)
- Add to watchlist
- Create an alert
- This stock can be held in a
![](https://online.hl.co.uk/img/hl/layout/security-up-arrow.gif)
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
![](https://online.hl.co.uk/img/hl/layout/security-up-arrow.gif)
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
Share news, reports & tips
-
Avacta Group appoints new non-executive chair
20 June 2024 16:09
(Sharecast News) - Life science company Avacta Group announced the appointment of Shaun Chilton as its non-executive chairman on Thursday, succeeding Eliot Forster, who was stepping down from the board with...
-
Avacta reports further progress in chemotherapy trial
23 May 2024 12:09
(Sharecast News) - Avacta Group announced the successful completion of the first cohort and the start of dosing for three patients in the second cohort of the second arm in its phase one trial of AVA6000, a...
-
Avacta reaches milestone in AVA6000 dose escalation
21 March 2024 13:10
(Sharecast News) - Avacta Group announced a significant milestone in its phase 1a dose escalation study of AVA6000, its lead 'preCISION' drug, on Thursday.
-
Avacta tumbles after raising £25.7m in heavily discounted placing
29 February 2024 08:27
(Sharecast News) - Healthcare therapeutics company Avacta tumbled on Thursday after a heavily discounted placing.
-
Avacta appoints new head of research and development
19 January 2024 11:18
(Sharecast News) - Oncology drugs and diagnostics developer Avacta announced the appointment of Dr Christina Coughlin as its new head of research and development for the therapeutics division on Friday.
-
Avacta appoints new chief business officer
19 December 2023 10:24
(Sharecast News) - Oncology drugs and diagnostics specialist Avacta Group announced the appointment of Dr Simon Bennett as the chief business officer of its therapeutics division on Tuesday.
-
Avacta hails "encouraging" clinical data from cancer-targeting study
13 December 2023 07:46
(Sharecast News) - Oncology drugs group Avacta has announced positive results from its lead pre|CISION programme, AVA6000, which it says has the potential to be "truly remarkable".
-
Avacta reports higher losses in first half
28 September 2023 07:57
(Sharecast News) - Cancer treatments and diagnostics group Avacta reported higher losses in the first half despite a doubling of revenues.
-
Avacta brings in clinical consultant as it hunts for permanent CMO
20 September 2023 11:57
(Sharecast News) - Oncology-focussed life science company Avacta Group announced a new consultancy pact with Dr Christina Coughlin on Tuesday.
-
Avacta upbeat on fresh data from chemotherapy trial
19 September 2023 13:39
(Sharecast News) - Life sciences company Avacta Group announced the successful completion of its sixth dose escalation cohort in the ALS-6000-101 phase one clinical trial on Tuesday, assessing the safety and...
-
Avacta completes fifth dose escalation in chemotherapy trial
21 June 2023 13:53
(Sharecast News) - Life sciences company Avacta announced the successful completion of the fifth dose escalation cohort in the phase 1 clinical trial for AVA6000 on Wednesday.
-
Avacta denies press speculation over potential fundraising
19 June 2023 10:16
(Sharecast News) - Oncology drug developer Avacta Group responded to recent market speculation over a potential fundraising initiative on Monday.
Company announcements Announcements
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.